Chris Kevil, PhD, Vice Chancellor for Research at LSU Health Shreveport, a leading cardiovascular researcher, and a pioneer in the treatment of peripheral artery disease, was recently appointed as Chair of JanOne’s Scientific Advisory Board.
In this role, Dr. Kevil will chair the Company’s scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of peripheral artery disease (PAD).
Dr. Kevil is considered a foremost expert in the development and analysis of various small molecules, biologics, disease indications, pharmaceutical, medical device, and drug delivery systems. At LSU Health Shreveport, he has established cutting-edge research programs regarding redox biology regulation of peripheral vascular diseases and has served as Dean of the School of Graduate Studies since 2017.
Dr. Kevil serves on numerous journal editorial boards including Cardiovascular Research, American Journal of Physiology – Heart and Circulation Physiology, Free Radical Biology and Medicine, and Frontiers in Oxidant Physiology. He has received numerous teaching and research grant awards, and has led research initiatives for the National Institutes of Health, the American Diabetes Association, the American Heart Association, and other professional societies.
